Corsair Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-47,726
| Closed | -$87.8K | – | 119 |
|
|
2023
Q2 | $87.8K | Sell |
47,726
-6,760
| -12% | -$15.6K | 0.03% | 94 |
|
|
2023
Q1 | $132K | Sell |
54,486
-12,115
| -18% | -$18K | 0.05% | 87 |
|
|
2022
Q4 | $95.2K | Sell |
66,601
-8,448
| -11% | -$16.5K | 0.04% | 90 |
|
|
2022
Q3 | $167K | Buy |
75,049
+23
| +0% | +$56 | 0.07% | 88 |
|
|
2022
Q2 | $155K | Hold |
75,026
| – | – | 0.05% | 94 |
|
|
2022
Q1 | $218K | Buy |
75,026
+16,369
| +28% | +$52.5K | 0.05% | 95 |
|
|
2021
Q4 | $188K | Buy |
+58,657
| New | +$200K | 0.04% | 83 |
|
|
2021
Q3 | – | Sell |
-16,911
| Closed | -$54K | – | 117 |
|
|
2021
Q2 | $54K | Buy |
+16,911
| New | +$53.2K | 0.01% | 125 |
|
|
2021
Q1 | – | Sell |
-116,250
| Closed | -$293K | – | 110 |
|
|
2020
Q4 | $293K | Buy |
116,250
+96,521
| +489% | +$210K | 0.07% | 61 |
|
|
2020
Q3 | $42K | Buy |
+19,729
| New | +$46.9K | 0.02% | 53 |
|
|
2017
Q3 | – | Sell |
-49,664
| Closed | -$548K | – | 85 |
|
|
2017
Q2 | $548K | Sell |
49,664
-6,027
| -11% | -$56.2K | 0.1% | 68 |
|
|
2017
Q1 | $466K | Sell |
55,691
-25,755
| -32% | -$181K | 0.08% | 65 |
|
|
2016
Q4 | $565K | Sell |
81,446
-2,040
| -2% | -$13K | 0.1% | 67 |
|
|
2016
Q3 | $425K | Sell |
83,486
-7,807
| -9% | -$46.6K | 0.07% | 72 |
|
|
2016
Q2 | $545K | Sell |
91,293
-8,597
| -9% | -$47.7K | 0.08% | 72 |
|
|
2016
Q1 | $454K | Sell |
99,890
-5,065
| -5% | -$22.5K | 0.06% | 80 |
|
|
2015
Q4 | $472K | Sell |
104,955
-12,240
| -10% | -$51.7K | 0.06% | 76 |
|
|
2015
Q3 | $372K | Sell |
117,195
-1,754
| -1% | -$5.32K | 0.04% | 83 |
|
|
2015
Q2 | $360K | Sell |
118,949
-658
| -0.6% | -$1.85K | 0.03% | 72 |
|
|
2015
Q1 | $353K | Sell |
119,607
-261,452
| -69% | -$856K | 0.03% | 79 |
|
|
2014
Q4 | $1.69M | Sell |
381,059
-228,045
| -37% | -$1.09M | 0.18% | 56 |
|
|
2014
Q3 | $3.14M | Sell |
609,104
-66,037
| -10% | -$352K | 0.32% | 49 |
|
|
2014
Q2 | $3.54M | Buy |
675,141
+32,792
| +5% | +$142K | 0.32% | 50 |
|
|
2014
Q1 | $2.67M | Sell |
642,349
-4,594
| -0.7% | -$15.7K | 0.27% | 51 |
|
|
2013
Q4 | $1.89M | Buy |
646,943
+23,723
| +4% | +$58.8K | 0.21% | 59 |
|
|
2013
Q3 | $1.57M | Buy |
623,220
+78,143
| +14% | +$185K | 0.2% | 66 |
|
|
2013
Q2 | $1.13M | Buy |
+545,077
| New | +$1.2M | 0.15% | 77 |
|
Other funds holding ENZ
HFA
TCM
PCM
RC
BCM
Corsair Capital Management's ENZ Position: Q3 2023 in Review
Corsair Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2023, closing a stake of 47,726 shares — an estimated $87.8K sold.
Corsair Capital Management first reported a position in ENZ in Q2 2013 and held it in 27 quarters. The position peaked at $3.54M in Q2 2014. 39 funds tracked by Wall St. Rank hold ENZ as of Q3 2023.
- Corsair Capital Management reported no remaining Enzo Biochem, Inc. position as of Q3 2023 after selling out during the quarter.
- Corsair Capital Management sold 47,726 Enzo Biochem, Inc. shares in Q3 2023, an estimated $87.8K.
- Corsair Capital Management first reported a position in Enzo Biochem, Inc. in Q2 2013 and held it in 27 quarters.
- Corsair Capital Management's Enzo Biochem, Inc. position peaked at $3.54M in Q2 2014.
- 39 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2023.
Based on Corsair Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.